<DOC>
<DOCNO>EP-0614362</DOCNO> 
<TEXT>
<INVENTION-TITLE>
PHARMACEUTICAL COMPOSITIONS BASED ON EBASTINE OR ANALOGUES THEREOF
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P900	A61K900	A61K900	A61K920	A61K31445	A61K914	A61P1108	A61K3145	A61P908	A61K914	A61P1100	A61K31445	A61K3145	A61K920	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	A61K	A61K	A61K	A61K	A61K	A61P	A61K	A61P	A61K	A61P	A61K	A61K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P9	A61K9	A61K9	A61K9	A61K31	A61K9	A61P11	A61K31	A61P9	A61K9	A61P11	A61K31	A61K31	A61K9	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
<APPLICANT-NAME>
RHONE POULENC RORER SA
</APPLICANT-NAME>
<APPLICANT-NAME>
RHONE-POULENC RORER S.A.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BOBEE JEAN-MARC
</INVENTOR-NAME>
<INVENTOR-NAME>
CONRATH GUILLAUME
</INVENTOR-NAME>
<INVENTOR-NAME>
GOUSSET GABRIEL
</INVENTOR-NAME>
<INVENTOR-NAME>
PONSOT MICHEL
</INVENTOR-NAME>
<INVENTOR-NAME>
VEILLARD MICHEL
</INVENTOR-NAME>
<INVENTOR-NAME>
BOBEE, JEAN-MARC
</INVENTOR-NAME>
<INVENTOR-NAME>
CONRATH, GUILLAUME
</INVENTOR-NAME>
<INVENTOR-NAME>
GOUSSET, GABRIEL
</INVENTOR-NAME>
<INVENTOR-NAME>
PONSOT, MICHEL
</INVENTOR-NAME>
<INVENTOR-NAME>
VEILLARD, MICHEL
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Solid pharmaceutical composition having 
improved dissolution properties, containing a compound 

corresponding to the formula: 

 
in which: 


R
1
 represents a thienyl group, a phenyl group 
optionally substituted with a halogen, an alkoxy group 

containing 1 to 6 carbon atoms or an alkyl group 
containing 1 to 6 carbon atoms, 
R
2
 represents a halogen atom, a hydrogen atom, 
an alkoxy group containing 1 to 6 carbon atoms or an 

alkyl group containing 1 to 6 carbon atoms, 
R
3
 represents a halogen atom, a hydrogen atom, 
an alkoxy group containing 1 to 6 carbon atoms, an alkyl 

group containing 1 to 6 carbon atoms, an alkylthio group 
containing 1 to 6 carbon atoms, a cycloalkyl group 

containing 5 or 6 carbon atoms or a group of formula: 

 
where R4 and R5 represent, independently of each other,  

 
a hydrogen atom or an alkyl group containing 1 to 6 

carbon atoms, R6 represents a cycloalkyl group containing 
3 to 6 carbon atoms or a hydroxymethyl or carboxyl group 

or an alkoxycarbonyl group containing 2 to 7 carbon 
atoms, 
W represents a carbonyl or hydroxymethylene 
group, and their salts; characterized in that the 

compound of formula (II) is micronized. 
Composition according to claim 1, 
characterized in that the active principle corresponds to 

the formula (II) in which: 

R
1
 represents a phenyl group 
R
2
 represents hydrogen 
R
3
 represents a tert-butyl group 
W represents a carbonyl group. 
Composition according to claims 1 and 2, 
characterized in that the active principle of formula 

(II) is hydrophilized. 
Composition according to claim 1, 
characterized in that the active principle of formula 

(II) has the following characteristics: 

maximum size smaller than 200 µm 
number-average particle size between 0.5 
and 15 µm 
preferably with 90 %, by number, of particles 
having a particle size smaller than 25 µm, 

and preferably smaller than 20 µm. 
Composition in compressed form, 
characterized in that it contains the active principle of 

claim 4. 
Process for the preparation of 
compositions according to claim 5, characterized in that: 


a micronization of the compound of formula 
(II) is performed in a first step 
a direct compression is performed in a second 
step. 
Process for the preparation of 
compositions according to claim 5, characterized in that: 


a micronization of the compound of formula  
 

(II) is performed in a first step 
a wet granulation, followed by a compression, 
is performed in a second step. 
Compositions in the form of oral 
lyophilizates, characterized in that they contain the 

active principle according to claim 4, a suspension agent 
chosen from gums, a sweetener and a diluent. 
</CLAIMS>
</TEXT>
</DOC>
